Abstract:Successful liver transplantation in a child is often a hard-won victory, requiring all the combined expertise of a dedicated pediatric transplant team. This article outlines the considerable challenges still facing pediatric liver transplant physicians and surgeons. In looking to the future, where should priorities lie to enhance the success already achieved? First, solutions to the donor shortage must be sought aggressively by increasing the use of from split-liver transplants, judicious application of living-donor programs, and increasing the donation rate, perhaps by innovative means. The major immunologic barriers, to successful xenotransplantation make it unlikely that this option will be tenable in the near future. Second, current immunosuppression is nonspecific, toxic, and unable to be individually adjusted to the patient's immune response. The goal of achieving donor-specific tolerance will require new consideration of induction protocols. Developing a clinically applicable method to measure the recipient's immunoreactivity is of paramount importance, for future studies of new immunosuppressive strategies and to address the immediate concern of long-term over-immunosuppression. The inclusion of pediatric patients in new protocols will require the ongoing insistence of pediatric transplant investigators. Third, the current immunosuppressive drugs have a long-term morbidity and mortality of their own. These long-term effects are particularly important in children who may well have decades of exposure to these therapies. There is now some understanding of their long-term renal toxicity and the risk of malignancy. New drugs may obviate renal toxicity, whereas the risk of malignancy is inherent in any nonspecific immunosuppressive regimen. Although progress is being made in preventing and recognizing PTLD, this entity remains an important ongoing concern. The global effect of long-term immunosuppression on the child's growth, development, and intellectual potential is unknown. Of particular concern is the potential for neurotoxicity from the calcineurin inhibitors. Fourth, recurrent disease and new diseases, perhaps potentiated by immunosuppressive drugs, must be considered. Already the recurrence of autoimmune disease and cryptogenic cirrhosis have been documented in pediatric patients. Now, a new lesion, a nonspecific hepatitis, sometimes with positive autoimmune markers, that may progress to cirrhosis has been recognized. It is not known whether this entity is an unusual form of rejection, an unrecognized viral infection, or a response to immunosuppressive drugs themselves. Finally, pediatric transplant recipients, like any other children, must be protected and nourished physically and mentally if they are to fulfill their potential. After liver transplantation the child's growth, intellectual functioning, and psychologic adaptation may all require special attention from parents, teachers, and physicians alike. There is limited understanding of how the enormous physical intervention of a liver transplantation affects a child's cognitive and psychologic function as the child progresses through life. The persons caring for these children have the difficult responsibility of providing services to evaluate these essential measures of children's health over the long term and to intervene if necessary. Part of the transplant physician's our duty to protect and advocate for children is to fight for equal access to health care. In most of the developing world, economic pressures make it impossible to consider liver transplantation a health care priority. In the United States and in other countries with the medical infrastructure to support liver transplantation, however, health care professionals must strive to be sure that the policies governing candidacy for transplantation and allocation of organs are applied justly and uniformly to all children whose lives are threatened by liver disease. In the current regulatory climate that increasingly takes medical decisions out of the hands of physicians, pediatricians must be even more prepared to protect the unique and often complicated needs of children both before and after transplantation. Only in this way can the challenges of the present and the future be met.

Liver transplantation for primary liver tumors in pediatrics. A case series

Liver transplantation for pediatric liver malignancies

Outcomes of Pediatric Hepatocellular Carcinoma: A Single‐Center Experience With Resection Versus Transplantation

Pediatric Liver Transplantation in 31 Consecutive Children

Liver Transplantation for Benign Liver Tumors

Advances in pediatric liver transplantation from the pediatric surgeon's perspective

Liver transplant for primary biliary tract neuroendocrine tumor in a nine‐year‐old girl

Case Report: ALPPS hepatectomy, an alternative to liver transplantation in central PRETEXT III hepatoblastomas: a case series

The Role of Liver Transplant in the Management of Hepatoblastoma Patients

Surgical treatment of liver tumor in childhood

Liver Transplantation for Primary Liver Cancer in Patients with Posthepatitic Cirrhosis

Thirty-Five Consecutive Pediatric Living Donor Liver Transplantation: Experiences and Lessons Learned from A Single Center

Liver transplantation for biliary atresia: A nationwide investigation from 1996 to 2013 in mainland China.

LIVER TRANSPLANTATION FOR THE TREATMENT OF CHILDREN WITH INHERITED METABOLIC LIVER DISEASES: SINGLE CENTER EXPERIENCE

Preliminary experience of parental living transplantation for hepatoblastoma in children

Risk for Recurrence in Long-Term Follow-Up of Children after Liver Transplantation for Hepatoblastoma or Hepatocellular Carcinoma

Liver transplantation. The pediatric challenge

Liver Transplant for Nonhepatocellular Carcinoma Malignancy

Laparoscopic Resection for Hepatic Masses in Children :A Report of 21 Cases

Indications for liver transplantation in pediatric patients

Liver Transplantation Using the Otherwise-Discarded Partial Liver Resection Graft with Hepatic Benign Tumor